Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named ...

And that's why Merck could credibly become the next big weight-loss stock. Before you rush to go buy shares of Merck, ...

Merck has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug to treat ...

Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in ...

The weight-loss biotech Viking Therapeutics ( VKTX 1.83%) saw its stock get absolutely slammed on Dec. 18, falling 18% as a ...

Merck & Co. is doubling down on getting into the white-hot weight-loss drug market, scooping up a pill developed in China. Merck said Wednesday it will pay Hansoh Pharma $112 million upfront for the ...

Merck has entered into a global licensing agreement with Chinese biopharmaceutical company Hansoh Pharma to develop an oral small molecule GLP-1 receptor agonist, HS-10535.

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

( MENAFN - Baystreet) Merck (NYSE:MRK) on Wednesday said it has snagged the rights to an experimental weight loss pill from ...

Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion. The oral drug has not yet entered ...